Abstract:Background Nilotinib inhibits the tyrosine kinase activity of ABL1/BCR-ABL1 and KIT, platelet-derived growth factor receptors (PDGFRs), and the discoidin domain receptor. Gain-of-function mutations in KIT or PDGFR alpha are key drivers in most gastrointestinal stromal tumours (GISTs). This trial was designed to test the efficacy and safety of nilotinib versus imatinib as first-line therapy for patients with advanced GISTs.Methods In this randomised, open-label, multicentre, phase 3 trial (ENESTg1), participants from academic centres were aged 18 years or older and had previously untreated, histologically confirmed, metastatic or unresectable GISTs. Patients were stratified by previous adjuvant therapy and randomly assigned (1: 1) via a randomisation list to receive oral imatinib 400 mg once daily or oral nilotinib 400 mg twice daily. The primary endpoint was centrally reviewed progression-free survival. Efficacy endpoints were assessed by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00785785.Findings Because the futility boundary was crossed at a preplanned interim analysis, trial accrual terminated in April, 2011. Between March 16, 2009, and April 21, 2011, 647 patients were enrolled; of whom 324 were allocated nilotinib and 320 were allocated imatinib. At final analysis of the core study (data cutoff, October, 2012), 2-year progression-free survival was higher in the imatinib group (59.2% [95% CI 50.9-66.5]) than in the nilotinib group (51.6% [43.0-59.5]; hazard ratio 1.47 [95% CI 1.10-1.95]). In the imatinib group, the most common grade 3-4 adverse events were hypophosphataemia (19 [6%]), anaemia (17 [5%]), abdominal pain (13; 4%), and elevated lipase level (15; 5%), and in the nilotinib group were anaemia (18; 6%), elevated lipase level (15; 5%), elevated alanine aminotransferase concentration (12; 4%), and abdominal pain (11; 3%). The most common serious adverse event in both groups was abdominal pain (11 [4%] in the imatinib group, 14 [4%] in the nilotinib group).Interpretation Nilotinib cannot be recommended for broad use to treat first-line GIST. However, future studies might identify patient subsets for whom first-line nilotinib could be of clinical benefit.

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Efficacy and Safety of the Imatinib in the Treatment of 73 Gastrointestinal Stromal Tumors

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

Observation of domestic imatinib on advanced gastrointestinal stromal tumors

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor

[Surgical Treatment for Patients with Advanced Gastrointestinal Stromal Tumor after Targeted Therapy].

Imatinib Mesylate Neoadjuvant Treatment for Rectal Malignant Gastrointestinal Stromal Tumor.

[Application of Perioperative Imatinib Mesylate Therapy in Initial Resectable Primary Local Advanced Gastrointestinal Stromal Tumor at Intermediate or High Risk].

Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.

Clinical Experience in Diagnosis and Treatment of Malignant Gastrointestinal Stromal Tumors

Imatinib Mesylate in Clinically Suspected Gastric Stromal Tumors.

Postoperative Imatinib in Patients with Intermediate Risk Gastrointestinal Stromal Tumor

[Imatinib Mesylate STI571 Therapy for Five Patients with Advanced Gastrointestinal Stromal Tumors].

Safety and Efficacy of Dasatinib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Single Arm, Multicenters, Phase 2 Trial.

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy

Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study

Nilotinib Versus Imatinib As First-Line Therapy for Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours (enestg1): a Randomised Phase 3 Trial.